FMC (FMC) On Brazil Herbicide Filing Looks Like A Recovery Story, But Is It Cheap

FMC (FMC) is back in focus after the company filed a regulatory dossier in Brazil for rimisoxafen, a new herbicide with two modes of action aimed at resistant weeds in key soybean and corn regions.

Investors have reacted quickly to the Brazil dossier, with FMC's share price up 6.64% over the last day to US$9.00. However, the 30 day share price return is down 30.61% and the 1 year total shareholder return has declined 70.48%, pointing to pressure that recent product news has only partly eased.

Scan other agricultural and materials stocks responding to product pipelines and regulatory milestones with our hand picked 19 high quality undiscovered gems for fresh ideas beyond FMC.

FMC has bounced hard on the rimisoxafen news, yet the share price is still sitting on deep 1 year and multi year losses. Does that skew the risk reward toward fresh buyers, or keep the balance of power with caution?

Most Popular Narrative: 34% Undervalued

FMC is trading at $9.00 against a widely followed fair value estimate of about $13.58, so the narrative leans toward a recovery story that depends heavily on new products and balance sheet repair actually coming through.

FMC needs the transition toward IP protected new active ingredients and collaborations, together with execution on manufacturing restructuring, to offset pricing pressure and generic competition in its legacy products.

FMC’s current valuation implies the market is not fully pricing in the company’s plan to grow revenues from new molecules and reduce net debt toward about US$2.6b with roughly 4x net leverage by year end 2026. This aligns with the view that the stock is currently priced below what this plan would suggest.

See why 51 investors see FMC as 34% undervalued.

Result: Fair Value of $13.58 (UNDERVALUED)

Still, the FMC story can fray quickly if regulatory scrutiny bites harder in key markets, or if pricing pressure and generic competition keep eroding its older products.

Find out about the key risks to this FMC narrative.

Next Steps

FMC’s story splits opinion, with some readers focused on valuation upside and others zeroed in on execution risks. Act quickly, review the underlying data, and pressure test both sides of the debate through the 3 key rewards and 3 important warning signs.

Looking for more FMC investment ideas beyond this story?

Do not stop your research with FMC alone. Broaden your watchlist in minutes using focused stock lists that surface financially grounded ideas tailored to different investing angles.

• Target potential mispricings by scanning companies that combine strong fundamentals with attractive valuations using the 27 high quality undervalued stocks.
• Zero in on resilience by reviewing a list of solid balance sheet and fundamentals (25 results) that highlights businesses with robust financial footing and cleaner balance sheets.
• Hunt for under-followed opportunities through a 19 high quality undiscovered gems that filters for quality metrics many investors may be overlooking right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com